Covaxin found to neutralise 617 variant of COVID-19: America's top pandemic expert Dr Fauci
Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3. Trial results later showed the vaccine has an efficacy of 78 per cent.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | COVID-19 | Emergency Medicine | India Health | Pandemics | Partnerships | Pharmaceuticals | Research | Vaccines | Virology